FGF‐21, as a mediator of energy homeostasis, represents a target for emerging new potentially beneficial therapies for obesity, dyslipidemia, and glucose dysregulation68, 69, 70 and possibly in the development of strategies in prevention or treatment of adverse metabolic effects of antipsychotics. Here, FGF21 is linked to obesity disorder.